Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of “Buy” by Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.33.

CNTX has been the topic of a number of recent analyst reports. D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a report on Wednesday, January 15th. JMP Securities initiated coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th.

Context Therapeutics Stock Performance

NASDAQ:CNTX opened at $0.83 on Thursday. The stock has a 50-day simple moving average of $0.95 and a two-hundred day simple moving average of $1.60. The firm has a market capitalization of $61.92 million, a PE ratio of -0.91 and a beta of 2.06. Context Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.75.

Institutional Trading of Context Therapeutics

Several hedge funds have recently made changes to their positions in CNTX. State Street Corp increased its stake in Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after acquiring an additional 19,800 shares during the last quarter. Clear Harbor Asset Management LLC increased its position in shares of Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock valued at $61,000 after purchasing an additional 21,804 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Context Therapeutics during the 4th quarter valued at approximately $29,000. Citadel Advisors LLC purchased a new stake in Context Therapeutics during the 4th quarter valued at $31,000. Finally, Millennium Management LLC lifted its position in Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after buying an additional 34,835 shares during the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.